Figure 1B Amplitude of low frequency fluctuation  (ALFF) differences between ALS and control groups without grey matter (GM) correction (A) and with GM correction (B).
Image credit: Luo, et.al. 2012 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgr[email protected]. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Personalized Medicine 2019
Sponsor: JPND
Description: This call invites multinational research teams to submit proposals for ambitious, innovative, multinational and multidisciplinary collaborative research projects to change the trajectory of neurodegenerative diseases through the development of precision medicine approaches. Proposals submitted under this call must focus on precision medicine in one or several of the following research areas: (1) Diagnosis (e.g. biomarkers, imaging data, omics approaches, big data analyses); (2) Prevention (e.g. biomarkers for studying novel treatments and interventions, co-morbidities, digital technologies, stratification within cohort studies and clinical trials); (3) Care (e.g. improvement of social and health care systems, molecular profiling, imaging, lifestyle data). Funding priorities: Alzheimer’s disease and other dementias, Parkinson’s disease and PD-related disorders, prion diseases, ALS/MND, Huntington’s disease, SCA and SMA.
Deadline: Pre-Proposal due by March 12, 2019.



NEW! Novel Biomarkers Ireland, Netherlands, UK
Sponsor: Weston Brain Institute
Description: This program provides funding for testing of novel biomarkers in human samples, data, and/or cohorts, in order to accelerate the development of therapeutics for neurodegenerative diseases of aging. Between £300,000 – £500,000 is available per project will be awarded over up to 3 years.
Deadline: Letter of Intent due by April 10, 2019.



Neuroscience Investigator Awards
Sponsor: The New York Stem Cell Foundation
Description: NYSCF is soliciting applications from early career investigators for Innovator awards in neuroscience. The goal of this initiative is to foster truly bold, innovative scientists with the potential to transform the field of neuroscience. Applicants are encouraged in the fundamental areas of developmental, cellular, cognitive, and translational neuroscience, broadly interpreted. Applicants need not be working in areas related to stem cells. The award provides $1.5M USD over 5 years and is open to researchers based at both national and international accredited academic and nonprofit research institutions.
Deadline: Application due by February 20, 2019.



Stem Cell Investigator Awards
Sponsor: The New York Stem Cell Foundation
Description: NYSCF is soliciting applications from early career investigators to fund research exploring the basic biology and translational potential of stem cells. The goal of this initiative is to foster bold and innovative scientists with the potential to transform the field of stem cell research, and advance understanding and use of stem cells in the development of treatments for human disease. The award provides $1.5M USD over 5 years and is open to researchers based at both national and international accredited academic and nonprofit research institutions.
Deadline: Application due by February 20, 2019.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by March 1, 2019.



ALS Research Program Therapeutic Development Award
Sponsor: US Department of Defense CDMRP
Description: The goal of the Amyotrophic Lateral Sclerosis Research Program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. The program supports post-discovery, preclinical development of therapeutics for ALS. The maximum award is $1,000,000 USD, or $1,250,000 USD if applying under the Therapeutically Relevant Marker Option. Preliminary data including identity and purity of the identified bioactive compound(s) are required. Collaboration with industry is encouraged.
Deadline: Pre-Proposal due by March 22, 2019.



ALS Research Program Therapeutic Idea Award
Sponsor: US Department of Defense CDMRP
Description: The goal of this program is to fund innovative preclinical research to promote the development of new treatments that may contribute to a cure for ALS. Funding priorities include screening methods or new ideas aimed at ALS drug or treatment discovery still in the early stages of development. A maximum of $500,000 USD will be awarded.
Deadline: Pre-Proposal due by March 22, 2019.



Clinical Research Grants
Sponsor: Muscular Dystrophy Association
Description: Clinical research grants are designed to support observational studies such as natural history, biomarker, and outcome measure studies. Clinical trials of compounds already on the market performed at academic medical centers may also be considered.
Deadline: Letter of Intent due by April 1, 2019.



Early Career Research Fellowship
Sponsor: Fight MND
Description: This Fellowship will support early-career researchers (within 5 years following award of their PhD) to lead a research project aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. A total of AUD $100,000 per annum for support of a 3-year full-time Fellowship, with an overall maximum of $300,000 for a 3-year award. Proposals for both discovery and translational research stages will be considered. Applications are invited for researchers based in institutions within Australia. Applicants must have completed their PhD within 5 years at the time of application.
Deadline: Application due by April 1, 2019.



IMPACT Grants
Sponsor: Fight MND
Description: IMPACT (IMProving and ACcelerating Translation) Grants support projects focused on one or more of the following key issues contributing to the lack of translation of effective treatments through to clinical trial for MND/ALS: disease heterogeneity; Lack of relevant preclinical models; a lack of reliable disease biomarkers; the challenge of drug delivery into the brain; a lack of effective targeted gene therapies; the untapped potential of stem cell therapy. These grants are for support of 2-year projects up to the value of AUD $250,000. Proposals for both discovery and translational research stages will be considered. Applications are invited for research based in institutions within Australia. Investigators at all academic levels are eligible to submit applications.
Deadline: Application due by April 1, 2019.



Mid-Career Research Fellowship
Sponsor: Fight MND
Description: This Fellowship will support mid-career researchers (5 – 12 years following award of their PhD) to lead a research project aimed at understanding the causes of MND/ALS, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. A total of AUD $100,000 per annum for support of a 3-year full-time Fellowship, with an overall maximum of $300,000 for a 3-year award. Proposals for both discovery and translational research stages will be considered. Applications are invited for researchers based in institutions within Australia. Applicants must have completed their PhD within 5 – 12 years at the time of application.
Deadline: Application due by April 1, 2019.



NeuroNEXT Small Business Innovation in Clinical Trials
Sponsor: NINDS
Description: This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).
Deadline: Application due by April 5, 2019.



Research Grants
Sponsor: Whitehall Foundation
Description: The Whitehall Foundation invites researchers to apply for their research grants. Funding priorities: basic research in neurobiology. Research grants are available to established scientists of all ages working at accredited institutions in the United States. The Foundation emphasizes the support of young scientists at the beginning of their careers and productive senior scientists who wish to move into new fields of interest. Research grants normally range from $30,000 to $75,000 per year.
Deadline: Letter of Intent due by April 15, 2019.



Starting Grants in ALS Basic Research
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: This aim of this award is to support early-career ALS scientists by providing funding for their basic research. Scientists across the globe are encouraged to apply! The funding is 100,000 CHF over 2 years.
Deadline: Application due by September 30, 2019.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Applications will begin to be accepted on September 6, 2019. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute.
Deadline: Application due by October 25, 2019.



CLIN 1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion an IND or IDE filing with the FDA and initiate clinical trial start-up with a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $6M USD. CIRM expects projects under this program to advance rapidly into the clinic and to achieve the proposed IND filing within 18 months.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity to accelerate the completion of a clinical trial for a promising stem or progenitor cell-based treatment that addresses an unmet medical need. The maximum award is $10-15M USD.
Deadline: Applications due by 2PM PST on the last business day of each month.



CLIN 3: Partnering Opportunity for Stem Cell Therapy Registration Clinical Trials
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded clinical trial projects that will directly enable product registration with the Food and Drug Administration (FDA). This award is only available to holders of a current CLIN2 award for a trial that has been deemed by FDA to be sufficient for registration.
Deadline: Applications due by 2PM PST on the the last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clinical Neuroscience Research Grants
Sponsor: Dana Foundation
Description: This grant funds "first-in-man" clinical studies of therapies being developed for brain diseases. Funded studies can receive up to $300,000 payable over three years. Potential applicants may submit a preliminary proposal and budget to determine full proposal eligibility. Applications are not solely restricted to clinical research scientists based in the United States.
Deadline: Applications are accepted on a rolling basis.



Early Phase Clinical Trials, Canada (Includes FTD)
Sponsor: Weston Brain Institute
Description: The Early Phase Clinical Trials Canada program provides funding to support clinical trials and/or clinical trial sub-studies that could accelerate the development of therapeutics for neurodegenerative disease aging, including FTD. Eligible principal investigators must be at or above the level of Assistant Professor or equivalent, and be affiliated with a CRA-qualified institution located in Canada. A maximum of $1,500,000 per project over up to 4 years.
Deadline: Applications are accepted on a rolling basis.



NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Applications are accepted on a rolling basis.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail